Journals / Turkish Journal of Veterinary and Animal Sciences / 2013 / Cilt: 37 - Sayı: 4

Evaluation of the pathogenicity of Candida zeylanoides in BALB/c mice

Pages
408–413
Publication Date
2013-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results showed that the injection of 1 × 108 cells of C. zeylanoides caused high mortality (group 1).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systemic candidiasis is an opportunistic infection caused by Candida species in animals.
📊
Key Findings & Data:The results showed that the injection of 1 × 108 cells of C. zeylanoides caused high mortality (group 1).
💡
Conclusion & Impact:In order to obtain the exact virulence factors in C. zeylanoides, this study should be continued in the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Candida zeylanoides · pathogenicity · virulence

Abstract

Systemic candidiasis is an opportunistic infection caused by Candida species in animals. The purpose of this study was to evaluate the pathogenicity of different doses of Candida zeylanoides in BALB/c mice. Thirty mice were selected in this study. Different doses of the yeast were intravenously inoculated to the animals. At first, clinical signs and survival time of infected mice were recorded. Then both mycological and histological examinations were performed for detection of Candida in different tissues. The results showed that the injection of 1 × 108 cells of C. zeylanoides caused high mortality (group 1). The mortalities occurred within 7-12 days (mean: 9.5 days) in group 2 (inoculated with 2 × 107 yeast) and 15-25 days (mean: 20 days) in group 3 (inoculated with 1 × 107 yeast cells) after infection. The kidneys had the highest burden of yeasts (6 × 104 CFU/g). The results of histological examination showed masses of round to oval budding yeast cells along with a few pseudohyphae in different tissues. These results provide evidence that the pathogenicity of C. zeylanoides is directly related to the inoculum size of the infecting species, representing the highest yeast burden in the kidneys of the infected BALB/c mice. In order to obtain the exact virulence factors in C. zeylanoides, this study should be continued in the future.

Özet

Systemic candidiasis is an opportunistic infection caused by Candida species in animals. The purpose of this study was to evaluate the pathogenicity of different doses of Candida zeylanoides in BALB/c mice. Thirty mice were selected in this study. Different doses of the yeast were intravenously inoculated to the animals. At first, clinical signs and survival time of infected mice were recorded. Then both mycological and histological examinations were performed for detection of Candida in different tissues. The results showed that the injection of 1 × 108 cells of C. zeylanoides caused high mortality (group 1). The mortalities occurred within 7-12 days (mean: 9.5 days) in group 2 (inoculated with 2 × 107 yeast) and 15-25 days (mean: 20 days) in group 3 (inoculated with 1 × 107 yeast cells) after infection. The kidneys had the highest burden of yeasts (6 × 104 CFU/g). The results of histological examination showed masses of round to oval budding yeast cells along with a few pseudohyphae in different tissues. These results provide evidence that the pathogenicity of C. zeylanoides is directly related to the inoculum size of the infecting species, representing the highest yeast burden in the kidneys of the infected BALB/c mice. In order to obtain the exact virulence factors in C. zeylanoides, this study should be continued in the future.

🔖

Cite This Article

KHOSRAVI, A. R., SHOKRI, H., NIKAEIN, D. (2013). Evaluation of the pathogenicity of Candida zeylanoides in BALB/c mice. Turkish Journal of Veterinary and Animal Sciences, Cilt: 37 - Sayı: 4, 408–413. https://ajindex.com/articles/121721

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Pfaller, M.A., Diekema, D.J.: Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol., 2004; 42: 4419–4431.
  2. Marr, K.A., Carter, R.A., Crippa, F., Wald, A., Corey, L.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis., 2002; 34: 909–917.
  3. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.B.: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004; 39: 309– 3 Zaoutis, T.E., Argon, J., Chu, J., Berlin, J.A., Walsh, T.J., Feudtner, C.: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis., 2005; 41: 1232– 12 Blumberg, H.M., Jarvis, W.R., Soucie, J.M., Edwards, J.E., Patterson, J.E., Pfaller, M.A.: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin. Infect. Dis., 2001; 33: 177–186.
  4. Singh, N.: Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis., 2001; 33: 1692–1696.
  5. Diekema, D.J., Messer, R.J., Hollis, R., Jones, N., Pfaller, M.A.: Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect. Control Hosp. Epidemiol., 2004; 25: 624–626.
  6. Puzniak, L., Teutsch, S., Powderly, W., Polish, L.: Has the epidemiology of nosocomial candidemia changed? Infect. Control Hosp. Epidemiol., 2004; 25: 628–633.
  7. Pfaller, M.A., Pappas, P.G., Wingard, J.R.: Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis., 2006; 43: 3–14.
  8. Viudes, A., Peman, J., Canton, E., Ubeda, P., Lopez-Ribot, J., Gobernado, M.: Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis., 2002; 21: 767–774.
  9. De Hoog, G.S., Cuarro, J., Gene, J., Figueras, M.J.: Atlas of Clinical Fungi. ASM, Washington D.C. 2000; pp. 1126. Levenson, D., Pfaller, M.A., Smith, M.A., Hollis, R., Gerarden, T., Tucci, C.B., Isenberg, H.D.: Candida zeylanoides: another opportunistic yeast. J. Clin. Microbiol., 1991; 29: 1689–1692.
  10. Crozier, W.J.: Two cases of onychomycosis due to Candida zeylanoides. Aust. J. Dermatol., 1993; 34: 23–25. Hazen,